Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry.

ABSTRACT:

Background

Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed. Global coagulation procedures such as thrombin generation assays (TGAs) or thromboelastometry are obvious candidates for testing. Information on the significance of TGA or thromboelastometry parameters in patients treated with emicizumab is limited.

Objectives

We performed a 2-step study to gain insight into the pattern of variation of TGA or thromboelastometry results in patients treated with emicizumab.

Methods

The first experiment was an in vitro investigation of the best conditions in terms of TGA reagent composition needed to show the best dose-response of

SUBMITTER: Tripodi A 

PROVIDER: S-EPMC12664498 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature